eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 23
 
Share:
Share:
more
 
 
abstract:
Original paper

18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study

Jarosław Czyż
,
Bogdan Małkowski
,
Artur Jurczyszyn
,
Norbert Grząśko
,
Rita Łopatto
,
Monika Olejniczak
,
Adriana Czyż
,
Anna Jachalska

Contemp Oncol (Pozn) 2019; 23 (1): 23-31
Online publish date: 2019/03/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim of the study
The aim of this study was to analyse the diagnostic accuracy of “18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT tracer in multiple mye­loma.

Material and methods
The analysed group included: patients with newly diagnosed active myeloma (eight patients); in very good partial remission or complete remission (VGPR or CR) after treatment (nine patients); and with active disease after relapse (15 patients).

Results
In patients with newly diagnosed myeloma, 64 lesions were found using CT and 83 lesions using 18F-FET. In six patients, the number of lesions using CT and 18F-FET was the same, and two had more lesions with the 18F-FET than with the CT. Patients in VGPR or CR had no FET-positive lesions. Fourteen out of 15 patients with active relapsed myeloma had 47 FET-positive lesions, CT assessment of the same group showed 282 lesions. In one patient with relapse soft tissue mass was found with 18F-FET but not with CT.

Conclusions
18F-FET can be a promising alternative to 18F-FDG PET/CT for myeloma-related bone disease diagnosis.

keywords:

multiple myeloma, 18F-FET, 18F-FDG PET/CT

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe